MedTrace Logo

A Study of EOC237 in Patients With Advanced Solid Tumor

NCT05895825 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-11-02

No results posted yet for this study

Summary

This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

EOC237

EOC237 for orally

Sponsors & Collaborators

  • Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-26
Primary Completion
2026-04-30
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05895825 on ClinicalTrials.gov